A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma

Digestion

Volumn 87, Issue 2, 2013, Pages 121-131

  Ertle, Judith M ^a   Heider, Dominik ^c   Wichert, Marc ^b   Keller, Benedikt ^a   Kueper, Robert ^d   Hilgard, Philip ^e   Gerken, Guido ^a   Schlaak, Joerg F ^a,b  

^a Department of Gastroenterology and Hepatology ^*  (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d WAKO Chemicals GmbH   (Germany)

^e Institut für Anästhesiologie Operative Intensivmedizin und Schmerztherapie   (Germany)

Author keywords

Fetoprotein; Des carboxy prothrombin; Hepatocellular carcinoma; Non alcoholic steatohepatitis; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; EUROPEAN; MIDDLE AGED; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SERODIAGNOSIS;

AGED; ALPHA-FETOPROTEINS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84873601726     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000346080     Document Type: Article

References (31)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
2. Chen J-G, Zhu J, Parkin DM, Zhang Y-H, Lu J-H, Zhu Y-R, Chen T-Y: Trends in the incidence of cancer in Qidong, China, 1978-2002. Int J Cancer 2006; 119: 1447-1454.
3. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
4. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
5. Simonetti RG, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972.
6. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
7. Gupta S, Bent S, Kohlwes J: Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50.
8. Chen J, Röcken C, Treiber G, Jentsch-Ulrich K, Malfertheiner P, Ebert MPA: Clinical implications of alpha-fetoprotein expression in gastric adenocarcinoma. Dig Dis 2003; 21: 357-362.
9. Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: 108-112.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
11. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-1431.
12. Bertino G, Ardiri AM, Boemi PM, Ierna D, Interlandi D, Caruso L, Minona E, Trovato MA, Vicari S, Li Destri G, Puleo S: A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med 2008; 50: 221-226.
13. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M, Nakano M: Serum levels of des-gamma- carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepato cellular carcinoma. Cancer 2000; 88: 544-549.
14. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM: Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect 2010; 23: 498-508.
15. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS: Des-gamma carboxyprothrombin can differentiate hepato cellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114-1121.
16. Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I: Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 2011; 102: 363-371.
17. Yamaguchi I, Nakamura K, Kitano H, Masuda Y, Kanke F, Kobatake S, Satomura S: Development of des-gamma-carboxy prothrom bin (DCP) measuring reagent using the LiBASys clinical analyzer. Clin Chem Lab Med 2008; 46: 411-416.
18. Yamagata Y, Shimizu K, Nakamura K, Henmi F, Satomura S, Matsuura S, Tanaka M: Simultaneous determination of percentage of Lens culinaris agglutinin-reactive alphafetoprotein and alpha-fetoprotein concentration using the LiBASys clinical autoanalyzer. Clin Chim Acta 2003; 327: 59-67.
19. Sing T, Sander O, Beerenwinkel N, Lengauer T: ROCR: visualizing classifier performance in R. Bioinformatics 2005; 21: 3940-3941.
20. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alphafetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
21. Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, Koike K, Kokudo N: Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatol Res 2011; 41: 1199-1207.
22. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS: Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.
23. Lok AS, Lai CL: alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110-115.
24. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M: Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010;55:2744-2755.
25. Forner A, Reig M, Bruix J: Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009; 137: 26-29.
26. Toyoda H, Kumada T, Tada T: Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma. Oncology 2011;81:61-65.
27. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS: Hepatocellualar carcinoma serum markers. Semin Oncol 2012;39:410-433.
28. Alkofer B, Lepennec V, Chiche L: Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011; 148: 3-11.
29. Ertle J, Dechêne A, Sowa J-P, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W-K, Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443.
30. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M: Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
31. Cabibbo G, Craxì A: Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2010; 14: 352-355.